XML 21 R8.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Cash flows from operating activities:    
Net loss $ (9,516) $ (288)
Adjustments to reconcile net loss to net cash provided by operating activities:    
Depreciation 1,453 1,781
Amortization of intangible assets 6,122 5,840
Amortization of deferred financing costs 280 280
Stock-based compensation expense 4,411 4,169
Deferred income taxes and other (414) (330)
Convertible Preferred Stock received in Biostage Settlement - Note 15 (3,900) 0
Changes in operating assets and liabilities:    
Accounts receivable 4,780 (4,294)
Inventories 252 (5,861)
Other assets 474 (439)
Accounts payable and accrued expenses (1,399) 2,454
Deferred revenue (851) 505
Other liabilities (540) (2,555)
Net cash provided by operating activities 1,152 1,262
Cash flows from investing activities:    
Additions to property, plant and equipment (1,590) (1,195)
Additions to intangible assets 0 (150)
Net cash used in investing activities (1,590) (1,345)
Cash flows from financing activities:    
Borrowing on bank line of credit 7,800 4,250
Repayment on bank line of credit (6,400) (2,200)
Repayment of term debt (3,186) (2,000)
Debt issuance costs 0 (102)
Proceeds from exercise of stock options and employee stock purchase plan 577 3,314
Taxes paid related to net share settlement of equity awards (1,628) (3,514)
Net cash used in financing activities (2,837) (252)
Effect of exchange rate changes on cash (38) (161)
Decrease in cash and cash equivalents (3,313) (496)
Cash and cash equivalents at beginning of period 7,821 8,317
Cash and cash equivalents at end of period 4,508 7,821
Supplemental disclosures of cash flow information:    
Cash paid for interest 2,314 1,577
Cash paid for income taxes, net of refunds $ 534 $ 577